Smoking Cessation Drugs
The majority of smokers who try to quit smoking do so from six to nine times during their lives. This research paper, which focuses on smoking cessation drugs, includes a survey the researcher conducted at three medical facilities. Forty participants relate details regarding their attempts to quit smoking.
"…Quitting smoking is one of the best things [one] can do for […his/her] health.
Most smokers try to quit 6-9 times in their lives"
- The U.S. Surgeon General ("Quitting can be…" 2009).
Quitting Smoking
"I know I need to quit smoking."
"I'm trying to quit."
"I plan to quit…."
"Quitting smoking is hard…."
As most smokers "realize" the damage smoking cigarettes does to the human body, many smokers regularly verbalize the statements denoting their intentions to quit smoking. The truth, albeit, as the introductory quote for this research paper purports, even though quitting smoking constitutes one of the best things a person can do for his/her health, quitting smoking simultaneously proves to be one of the hardest challenges a smoker counters. In fact, as The U.S. Surgeon General notes, "Most smokers try to quit 6-9 times in their lives." Smoking cessation drugs and/or methods, the focus for this research paper, therefore, the researcher asserts, qualify as subjects worthy of investigating.
The U.S. Surgeon General routinely investigates smoking cessation drugs; methods, and poses the question CHANTIX notes in their promotion for their stop smoking drug: "So why is it so hard to quit?" ("Quitting can be…" 2009). CHANTIX, the primary smoking cessation drug examined during this research effort, purports that understanding the reasons why quitting smoking may be difficult at times may prove helpful. The researcher asserts that it not only helpful, but prove vital for smokers who want to quit to understand more about smoking cessation drugs such as CHANTIX .
REVIEW OF LITERATURE
Tobacco addiction contributes to approximately 438,000 deaths in the United States each year, with smoking cigarettes constituting one of the most common preventable causes of death, on report asserts. Tobacco use kills five million people a year worldwide, another source stresses (Recent safety news, para. 2). Eliminating smoking could greatly reduce the occurrence of coronary heart disease and other forms of cardiovascular disease, including cardiovascular diseases such as heart attack, stroke, high blood pressure, atherosclerosis, thrombosis, coronary artery spasm, and cardiac arrhythmia (U.S. Surgeon General 2009).
Quitting smoking, albeit, proves to be difficult to most smokers. Right after a person starts to quit smoking, along with symptoms that accompany nicotine withdrawal, he/she may experience a number of short-term effects such as weight gain, irritability and anxiety. Ways to quit smoking include "cold turkey," step-by-step manuals, counseling or medical products may help replace or reduce nicotine addiction.
Advertisers, including drug companies, routinely market a number of stop-smoking products, scientifically "proven" to help a person quit smoking. These products, however, cannot do the "work" required to quit smoking. Using particular stop-smoking products, albeit, may help the smoker, determined to quit smoking, feel more comfortable and in control while he/she adjusts his/her life to be free from smoking.
The development of smoking cessation drugs dates back to 1971 when Pharmacia developed the first nicotine replacement product for smoking cessation, nicotine-laced chewing gum. Ensuring, contemporary nicotine replacement products can help relieve some of the withdrawal symptoms the smoker experiences when he/she attempts to quit smoking. Several nicotine replacement products currently available over-the-counter in the U.S. include two nicotine patches, nicotine gum and nicotine lozenges. In addition to over the counter products, a smoker wanting to quit smoking may obtain nicotine nasal spray, inhaler (Zyban) and the recently approved nicotine-free tablet (CHANTIX) by prescription. CHANTIX
CHANTIX asserts that its program includes a support plan with a steady, step-by-step approach designed to help the smoker quit smoking. "CHANTIX has been proven to help people quit" ("Quitting can be…" 2009), CHANTIX proclaims. Some of the ways CHANTIX reported differs from other quit-smoking products reportedly include:
In studies, 44% of CHANTIX users were quit during weeks 9 to 12 of treatment (vs. 18% on sugar pill).
CHANTIX is a non-nicotine pill.
CHANTIX can reduce the urge to smoke.
It comes with GETQUIT™, a support plan created just for CHANTIX users and designed to help you think and act like a quitter. ("Quitting can be…" 2009)
As prescribed drugs to help smokers quit smoking include side effects, as with other types of medication, the "patient" needs to follow his/her doctor's orders and use the prescribed smoking cessation...
When you see a sharp decline, this is an indication that the chances have increased that the person will have a heart attack. To determine effect of EPC's on heart disease in smokers, researchers would survey 15 different smokers. The results were that EPC's were lower in heavy smokers and increased if someone was a light smoker. When a person quit smoking, the underlying levels of EPC's would dramatically
Smoking Cessation Studies of six diverse communities in Chicago, poor women under welfare reform and Medicaid recipients as well as a focus group of seniors concerning smoking cessation showed that 1) populations do vary in their smoking behavior and ability to stop smoking and 2) programs must be developed to target specific demographics. Although prior studies showed that poorer individuals have worse health, comparatively less research has been conducted specifically on a
Developmental perspective was the concept that the nursing students participating in this study were typically younger than they patients they were caring for. This made it difficult for them to ask the "older" patient questions about a lifestyle they had been practicing for many years. Environmental constraints were noted that prevented the participants in the study from fully implementing best practice guidelines. The primary of which was time. They noted that
Evaluation Plan: Outcomes to be Assessed: The primary objective is to see that subjects of the program cease smoking and remain abstinent from tobacco use. This will be the primary outcome to be assessed therefore. Individuals in both the experiment and control groups would be consulted at the six-month juncture and the one year point in order to determine how many among them have remained abstinent from tobacco use in that duration
Topics include motivation, stress management, the effects of smoking, preparing to quit, relapse prevention, dealing with peer pressure, media awareness, support networks, and healthy lifestyles. Four optional booster sessions are offered after the program's conclusion" (NOT, 2009, CDC). The success of the NOT program is attributed to the way that the facilitators 'speak the language' of the participants. However, the need for having counselors who are familiar with the culture,
Smoking Behaviors Among Women… Smoking Behaviors Young Adult Women Smoking Behaviors among U.S. Women Ages 18-30 Smoking Behaviors among U.S. Women Ages 18-30 The issue of tobacco smoking is increasingly becoming an essential element to discussions about community and individual health. As smoking and all of its side effects and co-morbidities are the most preventable behaviors and diseases in the world (Bricker, Rajan, Andersen, & Peterson, 2005). The diseases and/or conditions directly associated with
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now